Addex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation
Addex Therapeutics (ADXN) said preclinical rat research published in the International Journal of Neuropsychopharmacology found its mGlu7 NAM ADX71743 increased wakefulness and reduced REM and non-REM sleep, while changing stress-related neurotransmitters across brain regions. The company said results support its mGlu7 program being advanced by Neurosterix. ADXN last traded at $5.79, premarket $6.19.
How this was made
The 30-second read
Why it matters
The publication adds mechanistic and behavioral evidence for targeting mGlu7 to regulate sleep-wake cycles and stress-related neurochemistry, potentially improving perceived program quality.
Market read
Traders may treat this as incremental de-risking for the mGlu7 thesis, but without clinical milestones it is unlikely to drive a major repricing.
What to watch
The article does not provide dose, effect size, translational biomarkers, or any update on Neurosterix’s clinical timeline, limiting decision usefulness for traders.
Background
Addex says ADX71743 is a selective mGlu7 negative allosteric modulator and that earlier work linked mGlu7 inhibition to anxiety and fear-memory reconsolidation.
Ticker impact
Addex reports preclinical data that its mGlu7 NAM ADX71743 increases wakefulness and reduces REM and non-REM sleep in rats.
Near-term impact likely limited, with sentiment support possible if investors view the data as de-risking the program.
The article discloses new preclinical findings and a CEO quote, but provides no clinical endpoints, trial timing, or regulatory/financing events that typically drive larger repricing.
Market effects
Highlights continued investor interest in glutamatergic allosteric modulation for CNS indications, especially sleep and stress circuitry.
No specific regional market linkage beyond general biotech sentiment.
Preclinical neuroscience findings are globally relevant but not tied to a specific jurisdictional decision.
Counterpoint
Preclinical sleep effects in rats may not translate to human efficacy or safety, so the market may discount the signal until clinical data arrive.
Key entities
- companyAddex Therapeutics
Clinical-stage biopharmaceutical company announcing preclinical publication on mGlu7 modulation via ADX71743.
- drug_candidateADX71743
Selective mGlu7 NAM prototype molecule discovered by Addex, tested in animal models for sleep and stress effects.
- companyNeurosterix
Launched by Addex and Perceptive Advisors in 2024, described as advancing the mGlu7 program.
